News

Trial shows osimertinib plus chemotherapy improves overall survival in EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus ...

Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC ...

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...